Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the objective tumor response rate of amrubicin or
standard topotecan therapy when administered as second-line therapy to ED-SCLC patients who
have chemotherapy sensitive recurrent or progressive.